Aug 19, 2026 · 8 min
Moderna rallies as buybacks and turnarounds test markets
Moderna Soars, SK Hynix Jumps, Estee Lauder Gains
The episode connects three sharp stock moves to bigger questions about biotech breakthroughs, shareholder returns, corporate recovery, and urban resilience.
- 1Moderna’s melanoma-vaccine results revive debate over whether the company can build a second act beyond COVID.
- 2SK Hynix’s buyback raises questions about shareholder value and the durability of the AI hardware trade.
- 3Estée Lauder’s stronger results offer early turnaround evidence despite restructuring, Asian weakness, and fierce cosmetics competition.
Don't miss
Moderna’s dramatic rally after positive late-stage melanoma-vaccine results becomes a test of whether the company has a post-COVID second act.
The brief
Moderna’s stock surges after promising late-stage melanoma-vaccine results, reviving the question of whether its mRNA platform can deliver a second act after COVID.
SK Hynix pairs a sharp move in its US listing with a large buyback and enhanced shareholder-return plan, prompting debate over whether buybacks create value or mainly lift earnings per share.
Estée Lauder gains on stronger earnings and improving organic sales, but its turnaround still faces a planned reduction of 10,000 positions, challenges in Asia, and intensifying cosmetics competition.
The episode then shifts from companies to cities, examining how AI, long-term planning, and innovative urban development could help fast-growing places become smarter and more resilient.
Dubai serves as the case study: rapid population growth becomes a test of whether ambitious urban-development blueprints can keep infrastructure aligned with change.
What was said on this episode
10 statements · 6 positive · 2 negative · 1 mixed · 1 neutral
Moderna stock rose 177%.
“we got 177% increase on that stock ticker MRNA”
Listen at 0:48
Moderna added $44 billion in market value.
“It added $44 billion in value.”
Listen at 0:58
Moderna’s surge caused short sellers $5.5 billion in losses.
“that jump suddenly delivered a five and a half billion dollar loss to any short sellers”
Listen at 1:04
Moderna’s trial was the first positive late-stage trial for mRNA cancer therapy.
“the first positive final stage trial for any mrna-based cancer therapy”
Listen at 1:27
SK Hynix’s buyback will not provide a permanent stock boost.
“It's not a forever boost to your stuff.”
Listen at 3:04
SK Hynix’s buyback does not fundamentally change the business.
“fundamentally nothing has changed”
Listen at 3:15
The durability of AI hardware inflation remains uncertain.
“how much of that kind of hardware inflation is going to persist?”
Listen at 3:23
AI will accelerate processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 5:52
Dubai responded effectively to its rapid population increase.
“they reacted very well to it”
Listen at 6:18
Dubai has a long-term urban-planning vision.
“They have a long-term urban planning vision”
Listen at 6:20
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Bloomberg L.P.
Bloomberg Audio StudiosBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.